Endo International PLC (NASDAQ:ENDP)’s share price was down 2.9% during mid-day trading on Friday . The stock traded as low as $17.30 and last traded at $17.37, with a volume of 1,916,143 shares traded. The stock had previously closed at $17.89.

Several equities analysts recently issued reports on ENDP shares. Nomura restated a “buy” rating on shares of Endo International PLC in a research report on Saturday, April 2nd. Leerink Swann restated an “outperform” rating and set a $37.00 price target (down from $51.00) on shares of Endo International PLC in a research report on Thursday, April 7th. Deutsche Bank AG reiterated a “buy” rating and issued a $61.00 price objective (down from $65.00) on shares of Endo International PLC in a research report on Monday, April 18th. JMP Securities began coverage on Endo International PLC in a research report on Thursday, April 21st. They issued an “outperform” rating and a $56.00 price objective on the stock. Finally, Citigroup Inc. cut their price objective on Endo International PLC from $72.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, April 29th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $39.19.

The company has a 50 day moving average of $16.83 and a 200 day moving average of $30.33. The stock’s market capitalization is $3.87 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Thursday, May 5th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.04. The firm earned $963.54 million during the quarter, compared to the consensus estimate of $960.96 million. During the same period last year, the company earned $1.17 EPS. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. On average, equities research analysts forecast that Endo International PLC will post $4.56 EPS for the current fiscal year.

In other news, Director Arthur J. Higgins acquired 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 10th. The shares were bought at an average price of $15.42 per share, with a total value of $169,620.00. Following the completion of the purchase, the director now directly owns 45,623 shares in the company, valued at $703,506.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul Campanelli acquired 13,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 10th. The stock was purchased at an average cost of $15.53 per share, for a total transaction of $201,890.00. Following the purchase, the insider now owns 201,069 shares of the company’s stock, valued at $3,122,601.57. The disclosure for this purchase can be found here.

A number of hedge funds recently made changes to their positions in the stock. Advantus Capital Management Inc boosted its stake in shares of Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock valued at $1,223,000 after buying an additional 476 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock valued at $16,737,000 after buying an additional 12,234 shares during the period. Finally, Cibc World Markets Corp bought a new stake in shares of Endo International PLC during the fourth quarter valued at about $47,081,000.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.